Mutations in SCN1A and SCN2A are associated with a wide spectrum of epilepsy related disorders in human. This dataset presented variants and clinical features of SCN1A and SCN2A genes. A total of 48 cases were presented, including 33 SCN1A mutations and 14 SCN2A mutations. While 22 mutations were novel in SCN1A and 11 were novel in SCN2A. The clinical features were included of gender, birth history, family history, seizure onset age, seizure types, frequency of seizures, initial and follow-up EEGs, brain MRI findings, antiepileptic drugs, prognosis and developmental data. The data can provide insights on novel mutations and different phenotypes of SCN1A and SCN2A.
Specifications

Value of the data
The data identify novel mutations in sodium channel SCN1A and SCN2A genes. The data show the difference of EEGs and prognosis between SCN1A and SCN2A mutations. The data might be useful for further function experiments in cellular and animal levels.
Data
Mutations in genes encoding the voltage-gated sodium channel are associated with seizurerelated syndromes. Different genes or different mutations in the same gene have distinct phenotypes [1, 2] . Clinical features and mutations of SCN1A and SCN2A genes are presented in Tables 1 and 2 .
Experimental design, materials and methods
Eight hundred and twenty-two children with epilepsy or neonatal severe seizures were performed whole exome sequencing (WES) or clinical exome sequencing (focused 2742 genes). We extracted genomic DNA in the peripheral blood of the children. DNA fragments were enriched for whole exome sequencing using the Agilent (Santa Clara, CA, USA) SureSelectXT Human All Exon 50 Mb kit, and for panel sequencing using the Agilent (Santa Clara, CA, USA) ClearSeq Inherited Disease panel kit. Our own database and public databases including the exome aggregation consortium, the 1000 Genome Project, and the dbSNP137 reported in the UCSC Genome Browser were used to screen the variants. Pathogenic variants or likely pathogenic variants were considered to be candidate variants. The candidate variants were validated by Sanger sequencing. SCN1A or SCN2A mutations were recruited in the database. Clinical information including sex, birth history, family history, seizure onset, seizure types, frequency of seizures, initial and follow-up EEGs, brain MRI findings, antiepileptic drugs, prognosis and developmental data were collected. 
